论文部分内容阅读
目的探讨肺癌患者在不同病理状态下血管性血友病因子(vWF)水平及其裂解酶(vWF-cp)活性的改变及临床意义。方法以残余胶原结合实验及ELISA分别测定2003年10月至2005年1月苏州大学附属第一医院呼吸科78例肺癌血浆vWF-cp和vWF,对其中23例合并胸腔积液的肺癌患者以放免法测定血清和胸水癌胚抗原(CEA)水平。结果(1)肺癌患者vWF抗原(vWFAg)(107.7±43.7)%显著高于正常对照组(71.3±49.5)%及肺良性疾病组(82.4±41.3)%(P<0.05),而vWF-cp活性水平在肺癌患者(59.2±21.5)%显著低于正常对照组(86.6±1.8)%和肺良性疾病组(79.4±13.3)%(P<0.05);二者在肺癌晚期广泛转移较局限期差异均有显著性;(2)血浆vWFAg与胸水CEA呈正相关,而vWF-cp与胸水CEA呈负相关。结论肺癌患者血浆vWFAg升高、vWF-cp降低,并与疾病进展有关。
Objective To investigate the changes and clinical significance of vWF and vWF-cp in patients with lung cancer under different pathological conditions. Methods The plasma vWF-cp and vWF of 78 lung cancer patients from 78 patients with respiratory tract in the First Affiliated Hospital of Soochow University from October 2003 to January 2005 were determined by residual collagen binding assay and ELISA. Twenty-three patients with lung cancer with pleural effusion were treated with radioimmunoassay Method for the determination of serum and pleural fluid carcinoembryonic antigen (CEA) levels. Results (1) The vWF antigen (vWFAg) in lung cancer patients was significantly higher than that in normal controls (71.3 ± 49.5%) and lung benign disease patients (82.4 ± 41.3%) (P <0.05) (59.2 ± 21.5)% in lung cancer patients was significantly lower than that in normal control group (86.6 ± 1.8)% and benign lung disease group (79.4 ± 13.3)% (P <0.05) (2) Plasma vWFAg was positively correlated with CEA of pleural effusion, while vWF-cp was negatively correlated with CEA of pleural effusion. Conclusion The plasma vWFAg level in patients with lung cancer is elevated and vWF-cp is decreased, which is related to the progress of the disease.